IRMD Iradimed Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: IRMD

Price (delayed)

$81.11

Market cap

$1.04B

P/E Ratio

42.92

Dividend/share

$1.27

EPS

$1.89

Enterprise value

$973.96M

?
Relative Growth: Rel. Growth: 95
Relative Strength: Rel. Strength: 37
Relative Valuation: Rel. Valuation: 17
Relative Profitability: Rel. Profitability: 94

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible products in the United States and internationally. It offers non-magnetic intravenous (IV) infusion pump systems, IV tubing sets, ...

Highlights
Iradimed's EPS has increased by 13% YoY and by 3.8% QoQ
Iradimed's net income has increased by 13% YoY and by 4% from the previous quarter
Iradimed's quick ratio has increased by 36% YoY but it has decreased by 5% from the previous quarter
IRMD's price to earnings (P/E) is 18% lower than its last 4 quarters average of 51.2 but 5% higher than its 5-year quarterly average of 40.0
Iradimed's gross margin has decreased by 2.1% YoY
Sector: Healthcare
Industry: Medical Devices
Website: http://www.iradimed.com
Peers: COO DXCM EW

Key stats

What are the main financial stats of IRMD

IRMD stock price

How has the Iradimed stock price performed over time
Intraday
2.13%
1 week
-3.38%
1 month
-5.02%
1 year
-3.57%
YTD
-16.62%
QTD
-5.93%

Financial performance

How have Iradimed's revenue and profit performed over time
Revenue
$89.34M
Gross profit
$67.46M
Operating income
$28.86M
Net income
$23.98M
Gross margin
75.5%
Net margin
26.8%
The company's operating income rose by 16% YoY and by 4.7% QoQ
Iradimed's net income has increased by 13% YoY and by 4% from the previous quarter
The company's revenue rose by 11% YoY and by 3.5% QoQ
The gross profit is up by 9% YoY and by 3% QoQ

Price vs fundamentals

How does IRMD's price correlate with its fundamentals

Growth

What is Iradimed's growth rate over time

Valuation

What is Iradimed stock price valuation
IRMD P/E details
P/E
42.92
P/B
9.74
P/S
11.61
EV/EBIT
31.3
EV/EBITDA
29.72
EV/Sales
10.9
IRMD's price to earnings (P/E) is 18% lower than its last 4 quarters average of 51.2 but 5% higher than its 5-year quarterly average of 40.0
Iradimed's EPS has increased by 13% YoY and by 3.8% QoQ
The price to book (P/B) is 21% lower than the last 4 quarters average of 12.0 but 14% higher than the 5-year quarterly average of 8.4
Iradimed's equity has increased by 8% YoY and by 4.6% QoQ
The price to sales (P/S) is 18% lower than the last 4 quarters average of 13.9 but 10% higher than the 5-year quarterly average of 10.3
The company's revenue rose by 11% YoY and by 3.5% QoQ

Efficiency

How efficient is Iradimed business performance
Iradimed's return on invested capital has increased by 4.5% YoY and by 3.3% QoQ
Iradimed's return on equity has increased by 4.4% YoY
The company's return on assets rose by 4% YoY and by 2.5% QoQ
Iradimed's return on sales has increased by 4.2% YoY

Dividends

What is IRMD's dividend history
Dividend details
DPS
$1.27
Dividend yield
1.57%
Payout ratio
67.2%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Iradimed financials performed over time
Iradimed's quick ratio has increased by 36% YoY but it has decreased by 5% from the previous quarter
The current ratio is up by 35% year-on-year but it has declined by 5% since the previous quarter
The company's debt is 100% lower than its equity
Iradimed's equity has increased by 8% YoY and by 4.6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.